News

Retension's Q3 net loss quadruples to $5.9M amid hypertension trial

What's the deal? Retension Pharmaceuticals (NASDAQ:RTSN) posted a third-quarter 2026 net loss of $5.9 million, up from $1.5 million a year earlier. Loss per share widened to $7.33 from $1.83. The jump traces almost entirely to one trial.

What's driving it? Research and development expense reached $5.0 million versus $1.4 million, and the company says its Phase 2b hypertension trial is the largest component. General and administrative costs rose to $990,759 from $299,574, bringing total operating expenses to $6.0 million.

What's the endgame? The Falls Church, Virginia clinical-stage company has no revenue and a single product candidate, RTN-001 — a once-daily, oral PDE5 inhibitor for uncontrolled hypertension. Initial Phase 2b data are expected in the first half of 2027, with a Phase 3 trial planned.

Why now? Spending ramped ahead of the company's initial public offering, which closed in October 2026. Cash stood at $9.2 million on September 30, down from $18.9 million at year-end 2025. Operating activities used roughly $9.4 million over nine months, against $2.5 million a year earlier.

The licence: Retension's subsidiary holds an exclusive sublicense from Redux Therapeutics under a November 2023 agreement, taking on milestone and royalty obligations to Kadmon, a Sanofi subsidiary. Royalties run at a low-teens share of net sales and sublicensing revenue.

What could go wrong? The company says existing cash plus net IPO proceeds should cover needs for at least 12 months, but it will still require substantial further funding. Points to watch are Phase 2b enrollment, spending levels, and how the proceeds are used.

The signal: Retension's widening losses are the familiar shape of a single-asset biotech pushing one candidate toward pivotal data — burning cash fast and leaning on fresh public funding to reach the next milestone.

Read more: kalkine.ca

Image credit: Generated with Gemini

More top stories